USFDA gives Voluntary Action Indicated for 3 units of Aurobindo Pharma in Telangana

17 Feb 2023 , 09:44 AM

On Thursday, Aurobindo Pharma Limited informed that its three manufacturing units in Jadcherla, Telangana, inspected by USFDA in January have been marked as voluntary action indicated (VAI).

VAI indicates that the USFDA will not take regulatory action because the objectionable conditions if discovered, are minor and may not warrant enforcement action.

The three VAI units are Unit I and Unit III, which manufacture tablets, capsules, and soft gel capsules, as well as a Derma manufacturing facility. All three facilities are in Jadcherla, Mahabubnagar District, Telangana.

USFDA inspected all three units between January 9 to January 18, 2023.

Recently, USFDA has also classified the company’s Unit-IX, n API intermediate facility situated at Gundlamachnoor, Sangareddy district, Telangana, as VPI. It was inspected between the period November 10 to November 18 last year.

Aurobindo Pharma has been struggling with regulatory issues lately, and hence this VAI classification comes as a relief for the pharma player.

At around 9.46 AM, Aurobindo Pharma was trading 0.46% lower at Rs477.70, as against the previous close of Rs479.90 on NSE. The counter opened at Rs477.50.

For feedback and suggestions, write to us at [e-mail]